HIV drug resistance and immune recovery study
Part of Immune system & allergy, Infections clinical trials.
This study looks at whether certain HIV drug resistance mutations affect how well your immune system recovers after starting HIV treatment. You may qualify if you are newly diagnosed, have never taken HIV meds before, and have a drug resistance test result available.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed HIV-1 infection.
- You must never have taken HIV medications before (be ART-naive).
- You must be older than 18 years.
- After starting HIV treatment, your viral load must become undetectable within 6 months.
- You must have had a drug resistance test (genotype) before starting treatment.
- You cannot have blood cancer or be using chemotherapy or other drugs that suppress the immune system or bone marrow.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how drug resistance mutations in HIV might affect how well certain treatments work, including two-drug regimens. It aims to help doctors choose the best medicines for each person.
This study compares how active the immune system is and how large the “hidden” HIV reservoir is in people on two different HIV treatment types. It may help researchers understand whether staying on a tenofovir-containing regimen leads to better control of HIV hiding in the body.
This study looks at how HIV continues to multiply (or stays suppressed) while you are taking antiretroviral therapy, using blood samples. It may help researchers better understand what HIV is doing during treatment and why some people experience changes like viral rebound.
This study looks at tiny cell “messengers” in blood and stool to understand how HIV behaves before and after starting treatment. You may be eligible if you have untreated HIV (or you’re a healthy volunteer) and can commit to many sample visits, including long-term storage for 20 years.
This study looks for HIV drug resistance in people who have been on a specific first-line HIV medication (TLD) for at least 6 months and still have detectable virus. It aims to understand if resistance is developing so that better treatments can be planned.
This study looks closely at how your immune system and HIV infection markers change right after a new HIV diagnosis. It may help doctors understand the earliest stages of HIV and improve how infections are measured and followed over time.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.